Drug and behavioral therapy in the treatment of lower urinary tract symptoms that persist after surgical treatment of benign prostatic hyperplasia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To evaluate the efficiency of behavioral and drug therapy aimed at reducing the severity of storage symptoms, and to determine the influence of therapy with an anticholinergic drug and a beta-3-adrenergic receptor agonist on the severity of lower urinary tract symptoms (LUTS) and urodynamic parameters in patients with LUTS that persist after surgical treatment of benign prostatic hyperplasia (BPH).

Materials and methods. A total of 115 patients with detrusor overactivity and LUTS that persisted one month after surgical treatment of BPH (IPSS score of 8 or more) were included in the study. Preoperatively, these patients, in addition to a standard examination, underwent urodynamic study (UDS), which revealed concomitant detrusor overactivity. Surgical procedures included transurethral resection of the prostate, endoscopic enucleation of the prostate gland (laser or bipolar), retropubic or laparoscopic simple prostatectomy. At inclusion in the study, patients were randomized into three groups. In group 1 (n=39), behavioral therapy was recommended. In Group 2 (n=39), M-anticholinergic (Solifenacin 5 mg once a day) was administered, while in Group 3 (n=37) a beta-3-adrenergic receptor agonist (Mirabegron 50 mg) was used. After two months of therapy, patients underwent repeated UDS and the severity of LUTS was assessed using the IPSS questionnaire.

Results. After two months of therapy, in each group a significant decrease in the total IPSS score, the sum of the storage and voiding symptom scores, and the median Quality of Life (QoL) score was achieved (p<0.05). At the same time, in groups with drug treatment a lower average IPSS and storage symptom scores (7.7±3.6 and 5.8±2.3 for the behavioral therapy group, 6.1±2.7 and 4.3±2.1 for the M-anticholinergic group, 6.3±3.1 and 4.5±2.2 for the beta-3 agonist group, respectively, p<0.05 when comparing the behavioral therapy group with each of the drug therapy groups) was seen. According to the control UDS, detrusor overactivity persisted in 97.4% of patients in the behavioral therapy group, 89.7% in the M-anticholinergic group, and 91.9% in the beta-3 agonist group. In each group, a significant (p<0.05) increase in the maximum cystometric capacity, volume of occurrence of the first involuntary bladder contraction, and a decrease in the maximum detrusor pressure during involuntary contraction were found. In each group, surgical treatment allowed to alleviate bladder outlet obstruction (BOO). In those who received M-anticholinergic drug and a beta-3-adrenergic receptor agonist, the maximum detrusor pressure during involuntary contraction was lower than with behavioral therapy (32±15.5 in the M-anticholinergic drug group vs. 33.9±15.2 in the beta-3-agonist group vs. 40.5±20.6 in the behavioral therapy group). According to the control UDS, the maximum cystometric capacity, volume of occurrence of the first involuntary bladder contraction, and the BOO index were comparable in all groups. Mirabegron caused side effects less frequently than Solifenacin; there were only 3 adverse events (8.1%) in the Mirabegron group and 11 (28.2%) in the Solifenacin group. The rate of refusal to continue therapy in patients taking beta-3-agonist (2.7%; n=1) was also lower than for Solifenacin (7.7%; n=3).

Conclusion. The study demonstrated the high efficiency of behavioral therapy and monotherapy with M-anticholinergic and beta-3-agonist in the treatment of LUTS that persist after surgical treatment of BPH. At the same time, both options of drug therapy demonstrate significantly greater efficiency than behavioral therapy in reducing the severity of LUTS and storage symptoms in particular, as well as in reducing detrusor pressure during its involuntary contractions. Therapy with the beta-3-agonist Mirabegron has a better safety profile than therapy with the M-anticholinergic Solifenacin, which results in greater patient compliance.

Full Text

Restricted Access

About the authors

Georgy V. Badakva

FGAOU VO N.I. Pirogov Russian National Research Medical University of the Ministry of Health of Russia; Pirogov City Clinical Hospital No.1

Author for correspondence.
Email: stubbz909@gmail.com
ORCID iD: 0000-0001-6450-0571
SPIN-code: 8792-7493

Ph.D. student at the Department of Urology and Andrology named after Academician N.A. Lopatkin, urologist at the Urologic Department

Russian Federation, Moscow; Moscow

Anvar G. Yusufov

FGAOU VO N.I. Pirogov Russian National Research Medical University of the Ministry of Health of Russia; «Kommunarka» Moscow Multidisciplinary Clinical Center of Moscow Health Department

Email: anvar.yusufov@mail.ru
ORCID iD: 0000-0001-8202-3844

Ph.D., associate professor at the Department of Urology and Andrology named after Academician N.A. Lopatkin, Head of the Urologic Department

Russian Federation, Moscow; Moscow

Daniil A. Bogdanov

FGAOU VO N.I. Pirogov Russian National Research Medical University of the Ministry of Health of Russia; «Kommunarka» Moscow Multidisciplinary Clinical Center of Moscow Health Department

Email: dancjaaa@gmail.com
ORCID iD: 0000-0001-6847-5684

Ph.D. student at the Department of Urology and Andrology named after Academician N.A. Lopatkin, Urologist

Russian Federation, Moscow; Moscow

Sergey V. Kotov

FGAOU VO N.I. Pirogov Russian National Research Medical University of the Ministry of Health of Russia; Pirogov City Clinical Hospital No.1; «Kommunarka» Moscow Multidisciplinary Clinical Center of Moscow Health Department

Email: urokotov@mail.ru
ORCID iD: 0000-0003-3764-6131

Ph.D., MD, professor, Head of the Department of Urology and Andrology named after Academician N.A. Lopatkin, Urologist at the Urologic Department, Head of University Clinic of Urology, Oncourology and Andrology

Russian Federation, Moscow; Moscow; Moscow

References

  1. Alyaev Yu.G., Glybochko P.V., Pushkar D.Yu. Urology. Russian guidelines. Moscow: Medforum publishing house, 2017: 544. Russian (Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М.: Медфорум, 2017; 544).
  2. Abrams P., Cardozo L., Fall M. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology, 2003;61(1):37–49. doi: 10.1016/s0090-4295(02)02243-4.
  3. Shahab N., Seki N., Takahashi R., Kajioka S., Takei M., Yamaguchi A., Naito S. The profiles and patterns of detrusor overactivity and their association with overactive bladder symptoms in men with benign prostatic enlargement associated with detrusor overactivity. Neurourol Urodyn. 2009;28(8):953–58. doi: 10.1002/nau.20706. PMID: 19260093.
  4. Jeong J., Lee H.S., Cho W.J., Jung W., You H.W. Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction. Urology. 2015;86(1):133–38. doi: 10.1016/j.urology.2015.03.033.
  5. Kotov S.V., Bogdanov D.A., Yusufov A.G. Complications and urinary disorders after surgical treatment of BPH by laser enucleation. Experimental and Clinical Urology. 2024;17(3):86–93. Russian (Котов С.В., Богданов Д.А., Юсуфов А.Г. Осложнения и нарушения мочеиспускания после проведенного оперативного лечения ДГПЖ методом лазерной энуклеации. Экспериментальная и клиническая урология. 2024;17(3):86–93) doi: 10.29188/2222-8543-2024-17-3-86-93.
  6. Tangriberganov M.R. Features of the treatment of benign prostatic hyperplasia in combination with clinical symptoms of an overactive bladder: abstract of the dissertation of the candidate of medical sciences: 14.01.23. Moscow, 2012. 25 p. Russian (Тангриберганов М.Р. Особенности лечения доброкачественной гиперплазии предстательной железы в сочетании с клиническими симптомами гиперактивного мочевого пузыря: автореферат дис. ... кандидата медицинских наук: 14.01.23. М., 2012. 25 с.).
  7. Lokshin K.L., Tangriberganov M.R., Gadzhieva Z.K. Contemporary drug therapy of irritative symptoms after TUR for BPH. Effective pharmacotherapy. Urologiya i Nefrologiya. 2012;1.Russian (Локшин К.Л., Тангриберганов М.Р., Гаджиева З.К. Современные возможности медикаментозной терапии при сохранении ирритативных симптомов после ТУР ДГПЖ. Эффективная фармакотерапия. Урология и нефрология. 2012;1).
  8. Gadzhieva Z.K. Urodynamic studies in the diagnosis and treatment of urinary disorders. Dr.Med.Sci. Thesis. M., 2009. 369 p. Russian (Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Автореф. дис. док. мед. наук. М., 2009. 369 с.).
  9. Gadzhieva Z.K., Kazilov Yu.B. New treatment options for combined lower urinary tract symptoms in patients with benign prostatic hyperplasia – prerequisites and benefits of Urologiia. 2017;1:.95–102. Russian (Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы – предпосылки и преимущества Урология. 2017;1:.95–102).
  10. Pushkar D.Yu. Symptoms of the lower urinary tract and benign prostatic hyperplasia. Urologiia. 2017;3-S3:4–18. Russian (Пушкарь Д.Ю. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы. Урология. 2017;3-S3:4–18) doi: https://dx.doi.org/10.18565/urol.2017.3-supplement.4-18
  11. Sexton C.C., Notte S.M., Maroulis C. et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65:567–585. doi: 10.1111/j.1742-1241.2010.02626.x
  12. Mirone V., Imbimbo C., Longo N. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007;51:57. doi: 10.1016/j.eururo.2006.07.050
  13. Steers W.D., Kolbeck S., Creedon D. et al. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest. 1991;88:1709. doi: 10.1172/JCI115488
  14. Steers W.D. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Uro. 2002;4(Suppl.):4:S7.
  15. Tarasov N.I., Ivaschenko V.A. Treatment of urination disorders after transurethral resection of the prostate gland. Experimental and Clinical Urology. 2016;1:98–105. Russian (Тарасов Н.И., Иващенко В.А. Лечение расстройств мочеиспускания после трансуретральной резекции предстательной железы. Экспериментальная и клиническая урология. 2016;1:98–105).
  16. Hsu F.C., Weeks C.E., Selph S.S. et al. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019;30:1603–1617. doi: 10.1007/s00192-019-04022-8
  17. Simanov R.N., Amdiy R.E., Al-Shukri S.K., Kuzmin I.V., Barysheva O.Y. Effectiveness of treatment of detrusor overactivity after transurethral resection of benign prostate hyperplasia. Urology reports. 2023; 13(1):5–13. Russian (Симанов Р.Н., Амдий Р.Э., Аль-Шукри С.Х., Кузьмин И.В., Барышева О.Ю. Эффективность лечения гиперактивности детрузора после трансуретральной резекции доброкачественной гиперплазии предстательной железы. Урологические ведомости. 2023;13(1):5–13). doi: 10.17816/uroved192493
  18. Gadzhieva Z.K. Rationale for the effectiveness and safety of the use of beta3-adrenomimetic in the drug-induced development of overactive bladder. Urologiia.. 2019;4:116–121. Russian (Гаджиева З.К. Обоснование эффективности и безопасности применения бета-3-адреномиметика в медикаментозном лечении гиперактивного мочевого пузыря. Урология. 2019;4:116–121) doi: 10.18565/urology.2019.4.116-122.
  19. Dawood O., El-Zawahry A. Mirabegron. [Internet]. Treasure Island (FL): StatPearls Publishing, 2024 https://www.ncbi.nlm.nih.gov/sites/books/NBK538513/

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Bionika Media